ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · IEX Real-Time Price · USD
1.940
-0.020 (-1.02%)
At close: Apr 26, 2024, 4:00 PM
1.980
+0.040 (2.06%)
After-hours: Apr 26, 2024, 4:03 PM EDT
ProQR Therapeutics Revenue
In the year 2023, ProQR Therapeutics had annual revenue of $10.58M with 128.23% growth. Revenue in the quarter ending December 31, 2023 was $6.91M with 436.02% year-over-year growth.
Revenue (ttm)
$10.58M
Revenue Growth
+128.23%
P/S Ratio
14.81
Revenue / Employee
$67,842
Employees
156
Market Cap
156.79M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 10.58M | 5.95M | 128.23% |
Dec 31, 2022 | 4.64M | 1.93M | 71.60% |
Dec 31, 2021 | 2.70M | -8.82M | -76.56% |
Dec 31, 2020 | 11.53M | 9.35M | 430.72% |
Dec 31, 2019 | 2.17M | -4.45M | -67.20% |
Dec 31, 2018 | 6.62M | 4.83M | 269.10% |
Dec 31, 2017 | 1.79M | -129.73K | -6.74% |
Dec 31, 2016 | 1.92M | -1.59M | -45.25% |
Dec 31, 2015 | 3.51M | 3.13M | 827.78% |
Dec 31, 2014 | 378.71K | 219.19K | 137.41% |
Dec 31, 2013 | 159.52K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionPRQR News
- 4 days ago - ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024 - GlobeNewsWire
- 5 days ago - ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting - GlobeNewsWire
- 8 days ago - ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio - GlobeNewsWire
- 6 weeks ago - ProQR Announces Year End 2023 Operating and Financial Results - GlobeNewsWire
- 3 months ago - ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 - GlobeNewsWire
- 4 months ago - ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration - GlobeNewsWire
- 5 months ago - ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets - GlobeNewsWire
- 6 months ago - ProQR Announces Third Quarter 2023 Operating and Financial Results - GlobeNewsWire